Vietnam's in vitro diagnostics (IVD) market is entering a new phase of growth as hospitals, diagnostic laboratories and healthcare providers invest in more advanced testing technologies to meet rising demand for earlier disease detection and precision medicine.
According to IMARC Group, Vietnam's In Vitro Diagnostics Market reached US$349.3 million in 2025 and is forecast to grow to US$503.6 million by 2034. The market continues to benefit from increasing healthcare investment, technological innovation and expanding access to diagnostic services across both the public and private healthcare sectors.
IVD technologies analyse blood, urine, tissue and other biological samples outside the body to detect, monitor and manage disease. They are fundamental to almost every area of modern healthcare, supporting clinical decision-making from routine health screening through to complex cancer diagnosis and personalised treatment.
The market covers a wide range of products and technologies, including:
- Clinical chemistry analysers
- Molecular diagnostics
- Immunoassay systems
- Haematology analysers
- Microbiology testing
- Histopathology and tissue diagnostics
- Point-of-care testing
- Genetic testing
- Companion diagnostics
- Laboratory automation and informatics
Several structural factors are supporting continued market expansion across Vietnam.
An ageing population is increasing demand for routine laboratory testing, while the growing prevalence of diabetes, cardiovascular disease and cancer is creating sustained demand for more sophisticated diagnostic technologies. Government programmes aimed at strengthening preventive healthcare and expanding access to diagnostic services are also encouraging hospitals to modernise laboratory infrastructure. At the same time, the continued growth of private hospital groups and independent laboratory networks is driving investment in high-throughput automated testing platforms.
One of the fastest-moving areas within the IVD sector is molecular diagnostics. Technologies such as PCR, next-generation sequencing (NGS) and liquid biopsy are becoming increasingly important for infectious disease testing, oncology and inherited disease diagnosis. As precision medicine develops across Asia, demand for biomarker testing and companion diagnostics is expected to rise significantly.
Artificial intelligence is also beginning to transform laboratory operations. AI-powered software is being integrated into digital pathology, laboratory information systems (LIS) and automated image analysis to improve workflow efficiency, reduce reporting times and support clinical decision-making. Combined with robotics and laboratory automation, these technologies are helping laboratories manage growing testing volumes while maintaining quality and consistency.
Point-of-care testing (POCT) is another important growth segment. Portable diagnostic devices are allowing clinicians to deliver rapid testing in emergency departments, outpatient clinics, pharmacies and even patients' homes. These technologies are particularly valuable in improving access to healthcare in rural and underserved areas while reducing pressure on central laboratories.
Vietnam's expanding biotechnology and pharmaceutical sectors are also increasing demand for advanced diagnostics. Clinical trials, personalised medicine, vaccine development and translatformational research all rely heavily on modern IVD technologies, creating additional opportunities for manufacturers of instruments, reagents, consumables and laboratory software.
Globally, the IVD industry continues to experience steady growth. IMARC Group estimates the Global In Vitro Diagnostics Market reached US$122.6 billion in 2025 and is expected to grow to US$186.6 billion by 2034, driven by increasing demand for early diagnosis, personalised medicine, laboratory automation and advances in molecular testing.
Leading manufacturers active in Vietnam and the wider global market include Roche Diagnostics, Abbott, Siemens Healthineers, Danaher (Beckman Coulter and Cepheid), Thermo Fisher Scientific, bioMérieux, Sysmex, QIAGEN, Becton Dickinson (BD) and Mindray. These companies continue to invest in molecular diagnostics, automation, digital pathology, artificial intelligence and integrated laboratory workflows to improve diagnostic speed, accuracy and efficiency.
As Vietnam continues to modernise its healthcare system and strengthen laboratory capabilities, the in vitro diagnostics sector is expected to remain one of the country's most strategically important healthcare technology markets. For manufacturers of diagnostic instruments, reagents, software, laboratory automation systems and molecular testing solutions, Vietnam offers significant opportunities driven by sustained investment in healthcare infrastructure, expanding clinical testing capacity and growing adoption of advanced diagnostic technologies.